Newsletter | August 27, 2025

08.27.25 -- Hear From Large Molecule CDMOs With Available Capacity For Customized Solutions

Considering outsourcing development and manufacturing? The Outsourced Pharma Capacity Update (OPCU), a free, interactive, digital event, convenes the industry's foremost CDMOs to provide up-to-date and direct insights into their available capacity and services, alongside specific facility and equipment updates. 

 

Discover the July 2025 event’s presenting sponsors in this newsletter to learn how they are best suited to help you to navigate the path to approval and commercialization.

FILL/FINISH

Novartis Contract Manufacturing

Novartis Contract Manufacturing introduces their fill and finish solutions and capacity. Explore an overview of the aseptic network of Novartis and the capabilities of each site.

Request Information

Novartis Contract Manufacturing

PCI Pharma Services

PCI is positioned to meet the future of sterile pharmaceutical development and manufacturing with technology and solutions for high-value biologics, complex formulations, and lyophilized drug products.

Request Information

PCI Pharma Services

Afton Scientific

Gain an overview of a new state-of-the-art Groninger filling line’s capabilities, production scale-up timelines, and how this new infrastructure supports product flexibility and long-term growth for partners.

Request Information

Afton Scientific

INCOG BioPharma Services

INCOG's balanced framework addresses the unique challenges of sterile manufacturing by integrating risk-based decision making with systematic capacity planning.

Request Information

INCOG BioPharma Services

LARGE MOLECULE DRUG SUBSTANCE & DEVELOPMENT

Resilience US, Inc.

Hear from Evan Pasenello, Head of Commercial Services, about how Resilience can support large molecule programs from early phase through clinical and commercial manufacturing.

Request Information

Resilience US, Inc.

Novartis Contract Manufacturing

Review biologics CDMO solutions and capacity offered by Novartis Contract Manufacturing. Specifically, understand capabilities in mammalian cell culture manufacturing and microbial fermentation.

Request Information

Novartis Contract Manufacturing

Cytovance Biologics

Thomas Kohl, Director of Business Development, shares microbial and mammalian capabilities and available capacity. Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients.

Request Information

Cytovance Biologics

FUJIFILM Biotechnologies

Review the strategic application of extensive expertise in microbial systems to meet the increasing demand for novel biologics. Cutting-edge capabilities ensure streamlined development and manufacturing processes.

Request Information

FUJIFILM Biotechnologies

Aragen

Aragen’s newly built cutting-edge biologics manufacturing facility launches with GMP capabilities from 50L to 2000L with a DP filling line and ADC conjugation suite set to redefine bioproduction in India.

Request Information

Aragen

ANALYTICS/LAB SERVICES

ReciBioPharm

ReciBioPharm’s specialized CDMO capabilities include development and manufacture for new biological modalities. Choose a CDMO with complete end-to-end services and in-house analytical capabilities.

Request Information

ReciBioPharm

Alcami

Alcami’s laboratory services can support many drug substance or drug product modalities, all product phases, and specialty laboratory services, including in-house microbiology, raw materials, and analytical development.

Request Information

Alcami

KBI Biopharma

Review real examples of how KBI Biopharma has supported its partners through transparency that empowers, integration that simplifies, methods that de-risk, and experience that accelerates.

Request Information

KBI Biopharma

Catalent

Pedro Morales, Director, Scientific Advisor of Biologics Analytical Services, explores how Catalent delivers tailored solutions through deep expertise and advanced capabilities.

Request Information

Catalent

ADC

Lonza

Leveraging Lonza's deep ADC expertise and experience, successfully develop high quality, commercially viable processes, spanning from pre-clinical development through commercial scale manufacturing.

Request Information

Lonza

Simtra BioPharma Solutions

With more than 65 years of sterile injectable manufacturing experience, Simtra offers world-class GMP sterile fill and finish services, deep scientific and technical expertise, and a uniquely collaborative approach.

Request Information

Simtra BioPharma Solutions

MilliporeSigma

With more than 15 years of experience as conjugation and linker-payload CDMO, MilliporeSigma has a proven track record of supporting clinical programs from IND to PPQ for commercialization.

Request Information

MilliporeSigma

EVENT REGISTRATION

Streamline your search for the ideal CDMO partner at the October 2025 OPCU virtual event! Ease the burden of a prolonged vetting process by connecting with multiple CDMOs to find the best partner for your project while getting an inside look at their capabilities and capacities.

 

Monday, October 6: Analytical Services

Monday, October 6: ADC

Tuesday, October 7: Large Molecule

Wednesday, October 8: Small Molecule Drug Substance/API

Wednesday, October 8: Small Molecule Drug Product/Finished Dosage Form

Thursday, October 9: Cell & Gene Therapy

Friday, October 10: Fill/Finish